Showing 181 - 200 results of 18,299 for search '(( significant impact decrease ) OR ( significant ((side decrease) OR (a decrease)) ))', query time: 0.64s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…”
  7. 187

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…”
  8. 188

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…”
  9. 189
  10. 190
  11. 191
  12. 192
  13. 193
  14. 194
  15. 195
  16. 196

    S1 Data - by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
  17. 197
  18. 198
  19. 199
  20. 200